5 results found.

Juvenile Myelomonocytic Leukemia Clinical Trial using Stem Cell Transplant

Masonic Cancer Center, University of Minnesota - Recruiting N/A to 18 years.
- Hematopoietic Cell Transplantation in Children With Juvenile Myelomonocytic Leukemia.
Stem Cell Transplant

Acute Lymphoblastic Leukemia, Acute Myelocytic Leukemia, Chronic Clinical Trial using clofarabine; cytarabine; busulfan; Plerixafor; cyclophosphamide; antithymocyte globulin (rabbit); stem cells; Tacrolimus; mycophenolate mofetil

St. Jude Children's Research Hospital - Recruiting N/A to 21 years.
- T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant.
clofarabine; cytarabine; busulfan; Plerixafor; cyclophosphamide; antithymocyte globulin (rabbit); stem cells; Tacrolimus; mycophenolate mofetil

Juvenile Myelomonocytic Leukemia Clinical Trial using busulfan; cyclophosphamide; melphalan; fludarabine phosphate; allogeneic hematopoietic stem cell transplantation; pharmacological study; laboratory biomarker analysis

Children's Oncology Group - Recruiting 3 Months to 18 years.
- A Randomized Phase II Study Comparing Two Different Conditioning Regimens Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) for Children With Juvenile Myelomonocytic Leukemia (JMML).
busulfan; cyclophosphamide; melphalan; fludarabine phosphate; allogeneic hematopoietic stem cell transplantation; pharmacological study; laboratory biomarker analysis

Chronic Myeloid Leukemia (CML), Acute Myelogenous Leukemia (AML); Clinical Trial using CliniMACS CD34+ Reagent System; Thiotepa; Cyclophosphamide; Alemtuzumab; Tacrolimus; Melphalan; Busulfan; Fludarabine

Columbia University - Recruiting N/A to 22 years.
- CD34+ Stem Cell Selection for Patients Receiving a Matched or Partially Matched Family or Unrelated Adult Donor Allogeneic Stem Cell Transplant for Malignant Disease.
CliniMACS CD34+ Reagent System; Thiotepa; Cyclophosphamide; Alemtuzumab; Tacrolimus; Melphalan; Busulfan; Fludarabine

Myelodysplastic Syndromes, or Juvenile Myelomonocytic Leukemia Clinical Trial

University Hospital Freiburg - Recruiting N/A to 215 Months.
- Prospective Non-randomized Multi-center Study for Epidemiology and Characterization of Myelodysplastic Syndromes (MDS) and Juvenile Myelomonocytic Leucemia (JMML) in Childhood.